See what’s in our product pipeline

VEL-101 Clinical Program

VEL-101, a novel investigational immunosuppressant formerly known as FR104, is a monoclonal antibody fragment that inhibits costimulation via direct CD28 blockade.¹ VEL-101 will be developed as a subcutaneous, at-home self-administration medication that may eliminate many of the toxicities seen with current standard of care immunosuppression.²

CD28 plays an essential role in T-cell activation, while CTLA-4 plays a key role in preventing or regulating T-cell activation.^1,3,4 As a direct blocker of CD28 on the T cell, VEL-101 has a unique mechanism of action. Direct blockade of CD28 on the T cell with VEL-101 preserves vital CTLA-4 inhibitory functions.^1,3,4 As a result of VEL-101's unique mechanism of action, it will be studied for prevention of acute rejection, preservation of regulatory T-cell function, and inhibition of donor-specific antibody production.^3,4

Animal and initial human studies have been completed with VEL-101, and based on the results, the development program is continuing.^1,3